In DLBCL, the survival-favoring EZH2 Y641 mutation is also a genetic mechanism underlying MHC-II deficiency, which leads to escape from immune surveillance and inferior prognosis [103]. This evidence concerns the gene EZH2 and diffuse large B-cell lymphoma.